45% Of Opioid Treatment Programs Now Offer Full Suite Of Medications For Opioid Use Disorder 

About 45% of opioid treatment programs (OTPs) offer all three approved medications for opioid use disorder (MOUD)—methadone, buprenorphine, and naltrexone, according to a recent report. The percentage of OTPs offering the full suite of MOUD increased from 33% in 2017, but uptake of buprenorphine and naltrexone has been uneven. The researchers recommended increased efforts to encourage OTPs to offer comprehensive MOUD treatment. 

All the OTPs studied offered methadone. The percentage of OTPs offering buprenorphine increased from 67.0% in 2017 to 85.1% in 2023. The percentage of OTPs offering naltrexone increased from 38.2% in 2017 to 52 . . .